Company executives had seen the drug as a potential multi-billion dollar opportunity in women’s health.

Positive study results in Phase 2 lead to a green light for the companies’ combination and plans to move their nasal spray ...

Industry veteran Catherine Owen Adams expects external innovation will be key to getting the brain-focused drug developer to “the next level.” ...

The biotech, which agreed to be bought by Supernus after clinical and commercial struggles, plans to lay off 338 employees by ...

The agency removed some onerous requirements for the complex cancer drugs and reduced restrictions on patients’ ...

New members of the ACIP panel raised questions about the evidence supporting COVID vaccines, and signaled plans to look at ...

The acquisition will expand AbbVie's exploration of in vivo CAR-T therapy, an ambitious approach that could sidestep some of ...

Backed by Perceptive Xontogeny Venture Funds and venBio Partners, the new biotech will make genetic medicines that don’t rely ...

The agency said it will evaluate whether regulatory action is needed after investigating the deaths of two patients treated ...

Many proposals to reform the PBM industry miss the forest for the trees, experts said this week. Instead, Congress should go ...

Lynozyflic is one of two bispecific antibodies Regeneron hopes will lift its oncology business. Meanwhile, IGM is the latest struggling biotech to agree to a buyout deal from Concentra.

The biotech, which earlier this year laid off nearly all of its staff, also announced a PIPE that will hand it $175 million ...